Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Receivables (2017 - 2024)

Historic Receivables for Serina Therapeutics (SER) over the last 8 years, with Q1 2024 value amounting to $65000.0.

  • Serina Therapeutics' Receivables rose 98333.33% to $65000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $65000.0, marking a year-over-year increase of 98333.33%. This contributed to the annual value of $57000.0 for FY2023, which is 132500.0% up from last year.
  • As of Q1 2024, Serina Therapeutics' Receivables stood at $65000.0, which was up 98333.33% from $57000.0 recorded in Q4 2023.
  • Serina Therapeutics' 5-year Receivables high stood at $507000.0 for Q1 2020, and its period low was $1000.0 during Q3 2022.
  • For the 5-year period, Serina Therapeutics' Receivables averaged around $134687.5, with its median value being $66000.0 (2023).
  • Its Receivables has fluctuated over the past 5 years, first crashed by 9894.74% in 2022, then soared by 660000.0% in 2023.
  • Quarter analysis of 5 years shows Serina Therapeutics' Receivables stood at $397000.0 in 2020, then crashed by 76.07% to $95000.0 in 2021, then crashed by 95.79% to $4000.0 in 2022, then soared by 1325.0% to $57000.0 in 2023, then grew by 14.04% to $65000.0 in 2024.
  • Its last three reported values are $65000.0 in Q1 2024, $57000.0 for Q4 2023, and $67000.0 during Q3 2023.